Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies
| Autor: | Steven K. H. Foung, Catherine Fauvelle, Thomas F. Baumert, Brian G. Pierce, Che C. Colpitts, Zhen-Yong Keck |
|---|---|
| Přispěvatelé: | Institut de Recherche sur les Maladies Virales et Hépatiques (IVH), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Pathology [Stanford], Stanford Medicine, Stanford University-Stanford University, Institute for Bioscience and Biotechnology Research [Rockville, MD, États-Unis] (IBBR), University of Maryland [College Park], University of Maryland System-University of Maryland System, Interaction virus-hôte et maladies du foie, R21 AI126582 |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Hepatitis C virus Immunology Hepacivirus Sciences du Vivant [q-bio]/Médecine humaine et pathologie Biology medicine.disease_cause Article 03 medical and health sciences Immune system Viral envelope Immunity vaccine Drug Discovery medicine Global health antibodies Animals Humans Pharmacology chemistry.chemical_classification Viral Vaccines Hepatitis C Hepatitis C Antibodies Hepatitis C Chronic medicine.disease immunity Antibodies Neutralizing Virology 3. Good health 030104 developmental biology chemistry biology.protein Molecular Medicine [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology Antibody Glycoprotein |
| Zdroj: | Expert Review of Vaccines Expert Review of Vaccines, Expert Reviews (formerly Future Drugs), 2016, 15 (12), pp.1535-1544. ⟨10.1080/14760584.2016.1194759⟩ |
| ISSN: | 1744-8395 1476-0584 |
| DOI: | 10.1080/14760584.2016.1194759 |
| Popis: | Introduction: With more than 150 million chronically infected people, hepatitis C virus (HCV) remains a substantial global health burden. Direct-acting antivirals have dramatically improved viral cure. However, limited access to therapy, late stage detection of infection and re-infection following cure illustrate the need for a vaccine for global control of infection. Vaccines with induction of neutralizing antibodies (nAbs) have been shown to protect successfully against infections by multiple viruses and are currently developed for HCV.Areas covered: Here we review the progress towards the development of vaccines aiming to confer protection against chronic HCV infection by inducing broadly nAbs. The understanding or viral immune evasion in infected patients, the development of novel model systems and the recent structural characterization of viral envelope glycoprotein E2 has markedly advanced our understanding of the molecular mechanisms of virus neutralization with the concomitant development of several vaccine candidates.Expert commentary: While HCV vaccine development remains challenged by the high viral diversity and immune evasion, marked progress in HCV research has advanced vaccine design. Several vaccine candidates have shown robust induction of nAbs in animal models and humans. Randomized clinical trials are the next step to assess their clinical efficacy for protection against chronic infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|